Cholestatic liver diseases: An era of emerging therapies

doi:10.12998/wjcc.v7.i13.1571

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7726)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

755

WORD

228

HTML

4876

Figures (1-2)

313

Tables (1-1)

151

Sum=6323

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

657

Download

746

Sum=1403

Jul 6, 2019 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Jul 6, 2019; 7(13): 1571-1581
Published online Jul 6, 2019. doi: 10.12998/wjcc.v7.i13.1571

Table 1 Novel Drugs for cholestatic liver diseases

Class	Drug	Mechanism of action	Trial
Bile acid	UDCA	Increases biliary bicarbonates; Anti-apoptotic, anti-inflammatory
Bile acid	Nor UDCA	Cholehepatic; shunting; Choleretic	NCT01755517
FXR ligands	Obetocholic acid	Reduced hepatic bile salt synthesis; Anti-inflammatory, Immunomodulator, Choleretic	POISE COBALT AESOP
	GS9674		NCT02854605
	LJN452/Tropifexor		NCT02516605
FGF-19 mimetics	NGM 282	Reduced bile acid synthesis	NCT02135536
TGR5 agonist	INT-777	Decreased bile acid pool, Choleretic, Anti-inflammatory, improves intestinal barrier	Not in trial
TGR5 agonist	INT-767		Not in trial
PPAR agonist	Banzfibrate	Increase biliary phospholipid concentration, Anti-inflammatory	NCT01654731
	MBX-8025		NCT02609048
	Elafibrinor		NASH trials
ASBT inhibitor	A4250	Dose dependent reduction in bile acids
	Maralixibat		CLARITY
	GSK2330672
Immunomodulator	FFP-104	Anti CD40 human monoclonal IgG4	NCT02193360

UDCA: Ursodeoxycholic acid; ASBT: Apical sodium-dependent bile salt transporter; FXR: Farnesoid X receptor; FGF: Fibroblast growth factor; TGR: Transmembrane G coupled receptor; PPAR: Peroxisome proliferator-activated receptor.

Citation: Samant H, Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G, Boktor M, Alexander JS. Cholestatic liver diseases: An era of emerging therapies. World J Clin Cases 2019; 7(13): 1571-1581
URL: https://www.wjgnet.com/2307-8960/full/v7/i13/1571.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i13.1571